Aclarion (NASDAQ:ACON) Price Target Lowered to $1.30 at Ascendiant Capital Markets

Aclarion (NASDAQ:ACON) had its price objective decreased by Ascendiant Capital Markets from $1.50 to $1.30 in a report released on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Aclarion Stock Performance

ACON stock opened at $0.18 on Wednesday. Aclarion has a 1 year low of $0.16 and a 1 year high of $7.40. The business has a 50 day simple moving average of $0.18 and a 200-day simple moving average of $0.24.

Institutional Trading of Aclarion

An institutional investor recently bought a new position in Aclarion stock. Virtu Financial LLC purchased a new stake in shares of Aclarion, Inc. (NASDAQ:ACON) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned about 1.40% of Aclarion at the end of the most recent quarter. Institutional investors and hedge funds own 7.52% of the company’s stock.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.